Revolution Medicines

Revolution Medicines (RVMD) received a non-transferrable FDA Commissioner’s National Priority Voucher (CNPV) for daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor. Daraxonrasib is in Phase 3 trials: RASolute 302 for pancreatic cancer and RASolve 301 for non-small cell lung cancer. Data from RASolute 302 is expected in 2026. While the CNPV can expedite FDA review, RVMD stated timelines remain unchanged. The voucher acknowledges the potential of daraxonrasib, but approval is not guaranteed.